💊 药物 A-Z 🧬 靶点 🛠 工具 📚 指南
全部药物 药物分类 治疗领域 不良反应
指南 术语表 时间轴
药物比较 药物旅程 药物家族
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Rilpivirine

CHEMBL175691 Phase 4 已批准 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
366.4 g/mol
LogP
4.5
Phase
4

A non-nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy for HIV-1 infection in treatment-naive patients with low viral loads. It is taken once daily and is available in combination pills that simplify HIV treatment regimens.

分子量

366.4000 g/mol

LogP

4.50

TPSA

97.40 Ų

Lipinski 五规则

符合

治疗领域

Cardiovascular Disease Generalized Anxiety Disorder Non-Alcoholic Fatty Liver Disease HIV/AIDS Hepatitis C

作用机制

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

二维结构

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1

                

                

                
                

                    
InChI

                    
InChI=1S/C22H18N6/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19/h3-9,11-13H,1-2H3,(H2,25,26,27,28)/b4-3+

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H18N6

                    

                    
                    

                        
HBD / HBA

                        
2 / 6

                    

                    
                    

                        
可旋转键数

                        
5

                    

                    
                    
                    

                        
重原子数

                        
28

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
常见问题

                

                    
                    

                        
                        

                            
A non-nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy for HIV-1 infection in treatment-naive patients with low viral loads. It is taken once daily and is available in combination pills that simplify HIV treatment regimens.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Rilpivirine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL175691.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6451164.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医疗免责声明

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.